Natalie Holles, Astellas
Astellas follows up $3B gene therapy buyout with $109M plan to accelerate a manufacturing boom
Just weeks after closing on their $3 billion Audentes buyout, Astellas is following up with a $109 million plan to build a new manufacturing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
